Featuring an interview with Dr Kanwal Raghav, including the following topics:
- Activity and tolerability of trastuzumab deruxtecan (T-DXd) in patients with HER2-expressing colorectal cancer (CRC) (0:00)
- Case: A woman in her mid 50s with multiregimen-refractory metastatic CRC receives T-DXd on a clinical trial (11:19)
- Case: A woman in her early 60s with advanced intrahepatic cholangiocarcinoma receives zanidatamab on a clinical trial (18:11)
- Molecular pathways and mechanisms of HER2 in cancer; clinical implications and future directions for gastrointestinal cancers (20:33)
- Evolving paradigm surrounding HER2 and other oncogene-addicted targets (29:32)
CME information and select publications
Research To Practice | Oncology Videos